The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
June 6th 2025
New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.
Roche’s CINtec PLUS Cytology Test Beneficial for Women at Higher Risk of Developing Cervical Cancer
November 16th 2021In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine whether their cervical cells were transforming to cervical pre-cancer.
Read More
Daily Medication Pearl: Sacituzumab govitecan-hziy (Trodelvy) for Breast Cancer
November 16th 2021Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.
Read More
New Rules on Mandatory COVID-19 Vaccinations: Applicability to Pharmacies
November 15th 2021CMS Interim Final Rule on mandatory COVID-19 vaccinations for all facilities participating in Medicare and Medicaid potentially impacts pharmacies that provide services under a contract or arrangement with these facilities.
Read More
Help Patients Safely Handle Medications to Improve Adherence
Addressing barriers such as cognitive impairment, cultural issues, and denial can help patients avoid adverse effects.
Read More
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the findings regarding the efficacy of combining and sequencing liver-directed therapy with systemic therapy.
Watch
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses areas of concern when approaching the combination and sequencing of liver-directed therapy with systemic therapy.
Watch
Combination of Casirivimab, Imdevimab Provides Long-Term Protection Against COVID-19
November 10th 2021A single 1200 mg subcutaneous dose of casirivimab and imdevimab (Regen-COV, Regeneron Pharmaceuticals), a preventative COVID-19 treatment, reduced the risk of contracting COVID-19 by 81.6% during months 2-8, according to additional results from a phase 3 trial published in The New England Journal of Medicine.
Read More